Evenity (romosozumab) carries an FDA black box warning for increased risk of heart attack, stroke, and cardiovascular death, making it one of the few osteoporosis drugs with such a serious safety label. The warning stems primarily from one large clinical trial that compared romosozumab to alendronate and found more cardiovascular events in the romosozumab group. But the picture is not as clean as a single boxed warning might suggest: a separate placebo-controlled trial found no elevated risk, real-world data from tens of thousands of patients have been mixed, and the biological explanation for why blocking sclerostin might harm blood vessels is still being pieced together.
Where the Cardiovascular Signal Came From
Two pivotal trials shaped the FDA’s view of romosozumab’s heart safety, and they pointed in different directions. The ARCH trial compared romosozumab to alendronate (a bisphosphonate) in postmenopausal women with osteoporosis and a history of fracture. That trial found a statistically significant increase in serious cardiac events and cardiac ischemia in the romosozumab group compared to alendronate. The FRAME trial, by contrast, compared romosozumab to placebo and found no significant increase in cardiac events or ischemia.1PubMed Central. Cardiovascular Safety of Romosozumab Compared to Commonly Used Anti-osteoporosis Medications in Postmenopausal Osteoporosis: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials
This divergence created a genuine scientific puzzle. If romosozumab itself were directly toxic to the heart and blood vessels, you would expect both trials to show harm. One explanation researchers have considered is that alendronate may have a protective cardiovascular effect, making the romosozumab group look worse by comparison rather than because romosozumab was causing events on its own. In other words, the gap between the two drugs in ARCH might partly reflect alendronate’s benefit rather than romosozumab’s danger. This is not settled science, but it is an important nuance when interpreting the data.
A smaller trial in men with osteoporosis added another wrinkle. In that study, cardiovascular serious adverse events were numerically higher in the romosozumab group (about 5%) compared to placebo (about 2.5%), though the trial was not large enough to draw firm conclusions. Among the romosozumab-treated men who had cardiovascular events, all had pre-existing cardiovascular risk factors at baseline.2The Journal of Clinical Endocrinology & Metabolism. A Phase III Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men With Osteoporosis
The Black Box Warning and What It Means in Practice
The FDA approved romosozumab in 2019 but attached its most serious warning: a black box stating that the drug may increase the risk of heart attack, stroke, and cardiovascular death. The European Medicines Agency issued similar cautions. Both agencies recommend that romosozumab be avoided in patients at high risk for cardiovascular disease, including anyone who has had a heart attack or stroke within the previous year.3PubMed Central. Romosozumab adverse event profile: a pharmacovigilance analysis based on the FDA Adverse Event Reporting System (FAERS) from 2019 to 2023
In practical terms, if you are being considered for romosozumab, your doctor should evaluate your cardiovascular history before writing the prescription. A recent heart attack, recent stroke, or poorly controlled cardiovascular risk factors (like unmanaged high blood pressure or advanced atherosclerosis) would typically disqualify you. This does not mean every person with any cardiovascular concern is automatically excluded; the warning is primarily aimed at people with recent or active cardiovascular disease. One paper noted that cardiovascular risk scoring tools are suitable for helping osteoporosis clinicians make this assessment, though different scoring systems are not interchangeable and the choice of tool matters.3PubMed Central. Romosozumab adverse event profile: a pharmacovigilance analysis based on the FDA Adverse Event Reporting System (FAERS) from 2019 to 2023
Why Blocking Sclerostin Might Affect Blood Vessels
Romosozumab works by blocking a protein called sclerostin, which normally acts as a brake on bone formation. Remove that brake, and bones grow denser and stronger. The problem is that sclerostin does not seem to limit its activity to bone. Research in animal models has shown that sclerostin plays a protective role against calcification of blood vessels. When sclerostin is absent or inhibited, the molecular signaling pathway it restrains (the Wnt pathway) becomes more active in vascular tissue, and that activity may promote the stiffening and calcification of artery walls.4PubMed Central. Sclerostin Protects Against Vascular Calcification Development in Mice
Studies in rats with vascular calcification found that the body appears to ramp up sclerostin production locally in calcified blood vessels, as if trying to put the brakes on further damage. This suggests that sclerostin functions as a negative feedback signal in the vasculature: when calcium starts building up where it should not, sclerostin levels rise to counteract the process.5PubMed Central. Sclerostin as Regulatory Molecule in Vascular Media Calcification and the Bone-Vascular Axis Blocking sclerostin with a drug, then, could theoretically remove that protective feedback loop. If you already have some degree of vascular calcification, taking away one of the body’s tools for limiting it is a reasonable cause for concern.
The Wnt signaling pathway also appears to play a role in atherosclerosis itself. Research on plaque-filled arteries found that Wnt signaling is activated in immune cells within artery plaques and seems to influence how those cells behave, including their movement in and out of plaques.6PubMed Central. Epigenome-guided analysis of the transcriptome of plaque macrophages during atherosclerosis regression reveals activation of the Wnt signaling pathway Whether enhancing Wnt activity through sclerostin blockade could meaningfully accelerate plaque instability in humans remains an open question, but the biological plausibility is there.
One group of researchers has proposed that combining romosozumab with a bisphosphonate could be a way to offset this vascular risk, since bisphosphonates appear to have opposing effects on the vessel wall: they tend to inhibit calcification and endothelial dysfunction rather than promote it.7PubMed. Cardiovascular Outcomes of Romosozumab and Protective Role of Alendronate This is still a hypothesis, not a proven clinical strategy, but it circles back to the ARCH trial puzzle. If alendronate has genuinely protective vascular effects, that could help explain why romosozumab looked worse by comparison.
What Real-World Data Show
Since romosozumab’s approval, researchers have tried to answer the cardiovascular question using data from patients treated outside clinical trials. The results have been inconsistent, which is part of why the debate continues.
An early analysis of the FDA’s adverse-event reporting database (FAERS) covering January 2019 through December 2020 found elevated reporting of major adverse cardiovascular events (MACE) with romosozumab compared to other drugs. The reporting odds ratio for MACE overall was about four times higher than expected, with individual signals elevated for heart attack, stroke, and cardiovascular death. However, this signal was heavily driven by reports from Japan, where the drug launched earlier and where the patient population skewed older and more male. Reports from the United States did not show a statistically significant elevation.8PubMed Central. Cardiovascular Safety Profile of Romosozumab: A Pharmacovigilance Analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS)
There are important caveats to adverse-event databases. They rely on voluntary reports, so they capture some events and miss others. They lack proper control groups and denominator data (the total number of people taking the drug), which makes it impossible to calculate a true event rate. When Japan first launched romosozumab, the contraindication for patients with recent cardiovascular disease was not yet in place, meaning some high-risk patients received the drug who would later be excluded by labeling changes.9PubMed Central. Cardiovascular safety of osteoanabolic agents
Japan’s own post-marketing safety data tell a somewhat more reassuring story. A safety report covering nearly 40,000 person-years of romosozumab exposure found incidence rates of stroke at 0.16 per 100 person-years and ischemic cardiovascular disease at 0.10 per 100 person-years, both of which were lower than rates seen in the general Japanese population.10Osteoporosis and Sarcopenia. Romosozumab and cardiovascular safety in Japan That comparison is imperfect, since romosozumab patients are a selected group, but it does suggest that when prescribers screen out high-risk patients, event rates do not appear to spike.
A real-world study following 847 postmenopausal women found that the rate of MACE during the first year of romosozumab treatment remained consistent, with no statistically significant jump between the first 90 days and the rest of the first year. The rate did increase after the first year of treatment, but the investigators noted that this later rise likely reflects the natural cardiovascular risk in an aging, osteoporotic population rather than a drug-specific effect, since romosozumab is only given for 12 months and these events came afterward.11PubMed Central. Cardiovascular outcomes of romosozumab treatment-real-world data analysis The study’s authors concluded that their findings challenge the idea that romosozumab increases cardiovascular events during the treatment window.
A large cohort study using Japan’s national claims database compared romosozumab directly to teriparatide (another bone-building osteoporosis drug). Among thousands of users of each drug, the rate of MACE was roughly 1.1 per 100 person-years with romosozumab and 1.2 per 100 person-years with teriparatide. The adjusted hazard ratio was 1.00, meaning no detectable difference in cardiovascular risk between the two drugs, regardless of whether patients had a history of cardiovascular events.12PubMed Central. Cardiovascular Risk of Romosozumab vs. Teriparatide: A Cohort Study Using Japan’s National Claims Database
Who Should Be Cautious and Who Can Likely Proceed
The evidence, taken as a whole, points toward a consistent message: romosozumab is most concerning for people who already have cardiovascular disease or significant cardiovascular risk factors. The patients who experienced cardiovascular events in the clinical trials and real-world databases tended to be older, had pre-existing conditions like diabetes or a history of heart disease, and were often already taking medications for cardiovascular problems. For someone with a clean cardiovascular history and well-managed risk factors, the available data are much more reassuring.
That said, “reassuring” is not the same as “proven safe.” The drug has only been on the market since 2019, and the largest controlled trial that showed a signal (ARCH) enrolled patients at genuinely high fracture risk, who also tend to be at higher cardiovascular risk simply because of their age and frailty. Separating the drug’s effect from the underlying risk profile of the people who need it most is genuinely difficult. If you and your doctor are weighing romosozumab, the conversation should include your specific cardiovascular history, any current cardiovascular risk factors, and whether the fracture-prevention benefit (which is substantial) outweighs the uncertain cardiovascular risk in your individual case.
What Happens After Romosozumab Treatment Ends
Romosozumab is only prescribed for 12 monthly doses. Once you stop, bone density starts to decline unless you transition to a maintenance therapy. This is not optional: research consistently shows that bone mineral density drops after romosozumab discontinuation without follow-up treatment.13PubMed. Verification of efficacy and safety of ibandronate or denosumab for postmenopausal osteoporosis after 12-month treatment with romosozumab as sequential therapy: The prospective VICTOR study
The two main options for follow-up are bisphosphonates (like alendronate or ibandronate) and denosumab (a different injectable drug that works by slowing bone breakdown). Head-to-head comparisons have generally favored denosumab for maintaining and extending the bone density gains achieved during romosozumab. In one randomized study, lumbar spine bone density increased an additional 5.4% with denosumab in the year after romosozumab, compared to 2.5% with ibandronate. Both drugs maintained gains at the hip and femoral neck, but denosumab showed a more robust edge at the spine.13PubMed. Verification of efficacy and safety of ibandronate or denosumab for postmenopausal osteoporosis after 12-month treatment with romosozumab as sequential therapy: The prospective VICTOR study A two-year follow-up study confirmed that both drug classes were effective, with denosumab showing superior sustained bone density improvements in the second year.14PubMed. Sequential therapy following romosozumab: real-world comparison of denosumab and bisphosphonates with 2-year follow-up
This matters for the cardiovascular question in an indirect but important way. If alendronate truly has a vascular-protective effect as some researchers have hypothesized, then transitioning to a bisphosphonate after romosozumab could theoretically help mitigate any lingering cardiovascular concern. This is speculative, and no trial has been designed to test this idea directly, but it is part of the reasoning that informs how some clinicians sequence these therapies.
The Difference Between Signal and Proof
The cardiovascular concern around romosozumab sits in a frustrating middle ground for both patients and doctors. There is a biological rationale for why blocking sclerostin could affect blood vessels. There is a signal from one large trial. And there is a regulatory response in the form of a black box warning. But the placebo-controlled trial showed no signal, the largest real-world cohort comparisons have not found excess risk when the drug is prescribed appropriately, and the pharmacovigilance data are clouded by reporting biases and population differences between countries.
A systematic review and network meta-analysis that pooled data from randomized controlled trials of various osteoporosis drugs found that the cardiovascular signal was not consistent across study designs, reinforcing the idea that the comparator (alendronate) in ARCH may explain part of the discrepancy.1PubMed Central. Cardiovascular Safety of Romosozumab Compared to Commonly Used Anti-osteoporosis Medications in Postmenopausal Osteoporosis: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials Put simply, the field has not reached consensus. Some researchers read the totality of evidence as concerning enough to warrant extreme caution. Others view the black box warning as appropriate for high-risk patients but overly conservative for the broader osteoporosis population, given that the drug’s fracture-prevention benefits are among the strongest of any available treatment.
Cost and Access Considerations
Romosozumab is expensive, and its restricted safety profile affects how health systems approach coverage. A cost-effectiveness analysis from Sweden modeled the use of romosozumab followed by alendronate in women aged 74 with a recent major osteoporotic fracture, compared to alendronate alone. The model followed patients from the start of treatment until death or age 100, weighing the added cost of romosozumab against the fractures it prevents and the quality of life gained.15PubMed Central. Cost-effectiveness of romosozumab for the treatment of postmenopausal women with severe osteoporosis at high risk of fracture in Sweden The economics generally favor the drug for the highest-risk fracture patients, which is also the population most likely to overlap with cardiovascular risk. This creates a tension that health systems and prescribers have to navigate on a case-by-case basis: the people who stand to benefit the most from the bone-building power of romosozumab are often the same people whose cardiovascular risk makes the drug most concerning.
Insurance coverage in the United States often requires prior authorization for romosozumab, and some insurers require documentation that the patient does not have contraindicated cardiovascular conditions. If you are prescribed romosozumab and your insurer denies coverage, the cardiovascular screening requirement is often the documentation hurdle. Having a clear cardiovascular risk assessment on file before the prescription is submitted can save time.
The Overlooked Role of Patients Who Were Never Studied
One thing that often gets lost in the discussion is who was actually enrolled in the major trials. The pivotal studies of romosozumab enrolled postmenopausal women and, in one trial, men with osteoporosis. The participants were overwhelmingly over 55, often over 70, and many had prior fractures. Younger patients, premenopausal women, and people with osteoporosis from other causes (like long-term steroid use or organ transplant) were not well represented. So while the cardiovascular debate is loud, it is based on evidence from a narrow demographic. If you fall outside that demographic and are being considered for romosozumab off-label, the cardiovascular data may not apply to you in the same way, but there is also no evidence saying you are safe. You and your doctor are essentially flying with less information.
Case series describing novel treatment sequences, like overlapping romosozumab with denosumab in patients with severe osteoporosis, have reported bone density increases of roughly 5 to 22% at the lumbar spine over 12 months with romosozumab, with no new vertebral fractures during the observation period.16PubMed Central. A novel sequential treatment approach between denosumab and romosozumab in patients with severe osteoporosis These reports did not flag cardiovascular concerns, but they involve tiny numbers of patients and short follow-up. They do, however, illustrate that clinicians are increasingly willing to use romosozumab in complex cases where fracture risk is severe enough to justify navigating the cardiovascular uncertainty.